TH
Trung Huynh UBS Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$30.7B
| $145.12 | $140 |
4%
downside
| Buy | 23 days ago |
|
2
Eli Lilly
LLY
$652B
| $726.81 | $895 |
23%
upside
| Buy | 28 days ago |
|
3
Amgen
AMGN
$153B
| $283.55 | $317 |
12%
upside
| Neutral | 1 month ago |
|
4
Regeneron Pharmaceuticals
REGN
$60.8B
| $573.22 | $584 |
2%
upside
| Neutral | 1 month ago |
|
5
Celldex Therapeutics
CLDX
$1.52B
| $22.86 | $38 |
66%
upside
| Buy | 3 months ago |
|
6
Pfizer
PFE
$142B
| $24.89 | $25 |
0%
upside
| Neutral | 4 months ago |
|
7
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $54 |
15%
upside
| Neutral | 4 months ago |
|
|
8
Eli Lilly
LLY
$652B
| $726.81 | $580 |
20%
downside
| Outperform | 2 years ago |
|
|
9
Eli Lilly
LLY
$652B
| $726.81 | $580 |
20%
downside
| Outperform | 2 years ago |
|
10
Johnson & Johnson
JNJ
$430B
| $178.38 | $175 |
2%
downside
| Neutral | 2 years ago |
|
|
11
Amgen
AMGN
$153B
| $283.55 | $200 |
29%
downside
| Outperform | 2 years ago |
|
|
12
Pfizer
PFE
$142B
| $24.89 | $40 |
61%
upside
| Neutral | 2 years ago |
|
|
13
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $72 |
53%
upside
| Neutral | 2 years ago |
|
14
Merck
MRK
$212B
| $84.71 | $126 |
49%
upside
| Outperform | 2 years ago |
|
15
AbbVie
ABBV
$375B
| $212.51 | $170 |
20%
downside
| Outperform | 2 years ago |
|